Testosterone and the Prostate: The Evidence So Far

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

It has traditionally been accepted that testosterone substitution in men with testosterone deficiency syndrome has the potential to harm the prostate. This theory originates from 1941 and is based on data presented for only two patients, one of whom had already been castrated. A review of the current peer-reviewed medical literature, however, has proved inconclusive. Whilst there is clear evidence that a reduction in serum testosterone to castration concentrations is able to reduce levels of prostate-specific antigen and delay the progression of established prostate cancer, it is difficult to prove the converse. Recent studies have shown that testosterone replacement has little effect on prostate tissue androgen levels and cellular function, whilst in men with prostate cancer, low serum testosterone levels were reported to be associated with the presence of extraprostatic cancer. Nevertheless, it is clear that the two classical contraindications for the administration of testosterone, that is, suspected or histologically proven prostate cancer and symptomatic benign prostatic hyperplasia, must be carefully respected.

Original languageEnglish
Pages (from-to)874-878
Number of pages5
JournalEuropean Urology, Supplements
Volume6
Issue number17
DOIs
Publication statusPublished - Nov 2007

Fingerprint

Testosterone
Prostate
Prostatic Neoplasms
Peer Review
Castration
Prostatic Hyperplasia
Prostate-Specific Antigen
Serum
Androgens
Neoplasms

Keywords

  • Prostate
  • Prostate cancer
  • Testosterone
  • Testosterone deficiency syndrome
  • Testosterone replacement therapy

ASJC Scopus subject areas

  • Urology

Cite this

Testosterone and the Prostate : The Evidence So Far. / Montorsi, Francesco.

In: European Urology, Supplements, Vol. 6, No. 17, 11.2007, p. 874-878.

Research output: Contribution to journalArticle

@article{248b8254fd2947a98fbbf2e23731eb51,
title = "Testosterone and the Prostate: The Evidence So Far",
abstract = "It has traditionally been accepted that testosterone substitution in men with testosterone deficiency syndrome has the potential to harm the prostate. This theory originates from 1941 and is based on data presented for only two patients, one of whom had already been castrated. A review of the current peer-reviewed medical literature, however, has proved inconclusive. Whilst there is clear evidence that a reduction in serum testosterone to castration concentrations is able to reduce levels of prostate-specific antigen and delay the progression of established prostate cancer, it is difficult to prove the converse. Recent studies have shown that testosterone replacement has little effect on prostate tissue androgen levels and cellular function, whilst in men with prostate cancer, low serum testosterone levels were reported to be associated with the presence of extraprostatic cancer. Nevertheless, it is clear that the two classical contraindications for the administration of testosterone, that is, suspected or histologically proven prostate cancer and symptomatic benign prostatic hyperplasia, must be carefully respected.",
keywords = "Prostate, Prostate cancer, Testosterone, Testosterone deficiency syndrome, Testosterone replacement therapy",
author = "Francesco Montorsi",
year = "2007",
month = "11",
doi = "10.1016/j.eursup.2007.08.003",
language = "English",
volume = "6",
pages = "874--878",
journal = "European Urology, Supplements",
issn = "1569-9056",
publisher = "Elsevier",
number = "17",

}

TY - JOUR

T1 - Testosterone and the Prostate

T2 - The Evidence So Far

AU - Montorsi, Francesco

PY - 2007/11

Y1 - 2007/11

N2 - It has traditionally been accepted that testosterone substitution in men with testosterone deficiency syndrome has the potential to harm the prostate. This theory originates from 1941 and is based on data presented for only two patients, one of whom had already been castrated. A review of the current peer-reviewed medical literature, however, has proved inconclusive. Whilst there is clear evidence that a reduction in serum testosterone to castration concentrations is able to reduce levels of prostate-specific antigen and delay the progression of established prostate cancer, it is difficult to prove the converse. Recent studies have shown that testosterone replacement has little effect on prostate tissue androgen levels and cellular function, whilst in men with prostate cancer, low serum testosterone levels were reported to be associated with the presence of extraprostatic cancer. Nevertheless, it is clear that the two classical contraindications for the administration of testosterone, that is, suspected or histologically proven prostate cancer and symptomatic benign prostatic hyperplasia, must be carefully respected.

AB - It has traditionally been accepted that testosterone substitution in men with testosterone deficiency syndrome has the potential to harm the prostate. This theory originates from 1941 and is based on data presented for only two patients, one of whom had already been castrated. A review of the current peer-reviewed medical literature, however, has proved inconclusive. Whilst there is clear evidence that a reduction in serum testosterone to castration concentrations is able to reduce levels of prostate-specific antigen and delay the progression of established prostate cancer, it is difficult to prove the converse. Recent studies have shown that testosterone replacement has little effect on prostate tissue androgen levels and cellular function, whilst in men with prostate cancer, low serum testosterone levels were reported to be associated with the presence of extraprostatic cancer. Nevertheless, it is clear that the two classical contraindications for the administration of testosterone, that is, suspected or histologically proven prostate cancer and symptomatic benign prostatic hyperplasia, must be carefully respected.

KW - Prostate

KW - Prostate cancer

KW - Testosterone

KW - Testosterone deficiency syndrome

KW - Testosterone replacement therapy

UR - http://www.scopus.com/inward/record.url?scp=34548778632&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548778632&partnerID=8YFLogxK

U2 - 10.1016/j.eursup.2007.08.003

DO - 10.1016/j.eursup.2007.08.003

M3 - Article

AN - SCOPUS:34548778632

VL - 6

SP - 874

EP - 878

JO - European Urology, Supplements

JF - European Urology, Supplements

SN - 1569-9056

IS - 17

ER -